XPO1 gene therapy restores cardiac function in rats with chronic induced myocardial infarction
Authors:
- María García-ManzanaresMGMaría García-Manzanares
- Carolina Gil-CayuelaCGCarolina Gil-Cayuela
- Luis Martínez-DolzLMLuis Martínez-Dolz
- José Ramón González-JuanateyJGJosé Ramón González-Juanatey
- Francisca LagoFLFrancisca Lago
- Manuel PortolésMPManuel Portolés
- Esther Roselló-LletíEREsther Roselló-Lletí
- Miguel RiveraMRMiguel Rivera
Preprint
Abstract
Background: In previous studies, we showed that several nuclear-cytoplasmic transport molecules were closely related to ventricular dysfunction in human heart failure. Particularly, the transcriptomic signature of XPO1 was highly expressed and inversely related to left ventricular function in heart failure patients of ischemic etiology. Therefore, we hypothesized that in a rat model of myocardial infarction treated with AAV9-shXPO1, an improvement in the ventricular function after a follow-up period may be observed. Methods: We induced myocardial infarction by coronary ligation in Sprague-Dawley rats (n=10), five of them received AAV9-shXPO1 treatment after four months and the other five infarcted rats did not receive any treatment. For non-failing controls, healthy Sham rats (n=5) received the placebo AAV9-scramble. Serial echocardiographic assessment was performed before, as well as, two and five months after intravenous injection. Results: AAV9-shXPO1-treated rats showed improved fractional shortening (16.8 ± 2.8 vs 24.6 ± 4.1%, P vs 3.52 ± 0.88mm, P vs 4.70 ± 0.93mm, P P <0.05). Discussion: At five months follow-up, ischemic AAV9-shXPO1-treated rats showed partial recovery of LV myocardial function. No secondary symptoms attributable to AAV9-shXPO1 were observed in skeletal muscle, liver and brain.Keywords
This publication has 17 references indexed in Scilit:
- Mortality from ischaemic heart disease by country, region, and age: Statistics from World Health Organisation and United NationsInternational Journal of Cardiology, 2013
- Heart Failure Induces Significant Changes in Nuclear Pore Complex of Human CardiomyocytesPLOS ONE, 2012
- SERCA2a gene therapy restores microRNA-1 expression in heart failure via an Akt/FoxO3A-dependent pathwayEuropean Heart Journal, 2012
- The evolution of heart gene delivery vectorsThe Journal of Gene Medicine, 2011
- Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID)Circulation, 2011
- Mitochondria in heart failureCardiovascular Research, 2010
- Mice over-expressing the myocardial creatine transporter develop progressive heart failure and show decreased glycolytic capacityJournal of Molecular and Cellular Cardiology, 2010
- Influence of heart failure on nucleocytoplasmic transport in human cardiomyocytesCardiovascular Research, 2009
- Recombinant Adeno-Associated Virus Serotype 9 Leads to Preferential Cardiac Transduction In VivoCirculation Research, 2006
- Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8Molecular Therapy, 2006